

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten! See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic in



PRODUCT INFORMATION



PGS-IN-1

Item No. 37666

CAS Registry No.: 102271-49-8

Formal Name: (E)-3-[[3,5-bis(1,1-dimethylethyl)-4-

hydroxyphenyl]methylene]dihydro-

2(3H)-furanone

Synonyms: KME-4, PGS Inhibitor 1,

PG Synthetase Inhibitor 1,

Prostaglandin Synthetase Inhibitor 1

MF: $C_{12}H_{26}O_3$ FW: 302.4 **Purity:** ≥95%

UV/Vis.: λ_{max} : 218, 238, 318 nm

Supplied as: A solid -20°C Storage: Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

PGS-IN-1 is supplied as a solid. A stock solution may be made by dissolving the PGS-IN-1 in the solvent of choice, which should be purged with an inert gas. PGS-IN-1 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of PGS-IN-1 in ethanol is approximately 5 mg/ml and approximately 25 mg/ml in DMSO and DMF.

Description

PPGS-IN-1 is a non-steroidal anti-inflammatory drug (NSAID) and a dual inhibitor of COX and 5-lipoxygenase (5-LO; IC₅₀s = 0.44 and 0.85 μ M, respectively).¹ It is selective for 5-LO over 12-LO $(IC_{50} = >100 \mu M)$ for the rabbit enzyme). Oral administration of PGS-IN-1 (10 mg/kg per day) inhibits paw swelling and bone damage in a rat model of M. butyricum-induced arthritis.²

References

- 1. Hidaka, T., Takeo, K., Hosoe, K., et al. Inhibition of polymorphonuclear leukocyte 5-lipoxygenase and platelet cyclooxygenase by α -(3,5-di-tert-butyl-4-hydroxybenzylidene)- γ -butyrolactone (KME-4), a new anti-inflammatory drug, Jpn. J. Pharmacol. 38(3), 267-272 (1985).
- 2. Hidaka, T., Hosoe, K., Yamashita, T., et al. Effect of α-(3,5-di-tert-butyl-4-hydroxybenzylidene)-γbutyrolactone (KME-4), a new anti-inflammatory drug, on the established adjuvant arthritis in rats. Jpn. J. Pharmacol. 42(2), 181-187 (1986).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 04/03/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM